TriviumVet’s felycin®-CA1 has been granted conditional approval by the United States Food and Drug Administration (FDA), marking a significant milestone in feline cardiac care.
This is the first-ever approval for a feline cardiology drug and the first product approved specifically for use in cats with feline hypertrophic cardiomyopathy (HCM) for any indication.
Felycin®-CA1 (sirolimus delayed-release tablets), administered once weekly, is indicated for managing ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.
“Felycin®-CA1 is the first and only medication shown to reduce the ventricular hypertrophy that is the principal feature of subclinical HCM.
“It provides a valuable treatment option for veterinarians and pet owners and will transform the way feline HCM is managed,”…